Project Grant R43HL162148
- Federal Project Grant Award Summary The National Heart, Lung, and Blood Institute (NHLBI) awarded a $748,970 Project Grant to the University of Pennsylvania on August 15, 2025, under the Cardiovascular Diseases Research program (CFDA 93.837) to advance understanding of evidence-based practice implementation in intensive care units (ICUs) managing mechanically ventilated patients. The research project, which runs through May 31, 2029, will deliver a comprehensive analysis of how contextual...
- Federal Grant Award Summary The National Heart, Lung, and Blood Institute (NHLBI) awarded a $178,846 Project Grant to the University of California, San Diego, effective August 1, 2025, through July 31, 2030, under the Cardiovascular Diseases Research program (CFDA 93.837). This research initiative investigates optimal ventilator management strategies for patients with Acute Respiratory Distress Syndrome (ARDS) on veno-venous extracorporeal membrane oxygenation (V-V ECMO). The project will...
- Federal Project Grant Award Summary SafeBVM Corp. received a $499,932 Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837), with an award date of September 17, 2025, and completion date of August 31, 2026. The grant funds the integration of SafeBVM's SOTAIR device with capnography technology to standardize manual ventilation techniques and improve patient outcomes in emergency and critical care settings....
- Federal Project Grant Summary The Pediatric Prehospital Ventilation Trial (PEDI-VENT), funded by the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837), is an ancillary study designed to analyze optimal ventilation strategies for critically ill and injured children in emergency medical services (EMS) settings. Awarded to Oregon Health & Science University on September 19, 2025, with $1,632,238 obligated through June 30, 2029,...
- Project Grant Award Summary The National Heart, Lung, and Blood Institute (NHLBI) awarded Vanderbilt University Medical Center a $185,578 Project Grant on September 25, 2025, under the Cardiovascular Diseases Research program (CFDA 93.837) to conduct the Mode of Ventilation During Critical Illness at Multiple Centers (MODEM) Trial through July 31, 2030. Principal Investigator Dr. Kevin P. Seitz, an instructor in the Division of Allergy, Pulmonary, and Critical Care Medicine at Vanderbilt, will...
- This $498,000 project grant, awarded by the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) on August 16, 2025, supports research conducted by Dr. Zhengjie Zhou at Temple University in Philadelphia, PA through July 31, 2028. The award funds the research and development phase (R00 portion) of an NIH Mentored Career Award (K99/R00) focused on formulating novel lung-targeting lipid nanoparticles (LNPs) for cell-specific messenger...
- Federal Grant Award Summary The National Heart, Lung, and Blood Institute (NHLBI) awarded Boston Children's Hospital a Project Grant of $889,188 (awarded May 21, 2025; completion date March 31, 2029) under the Cardiovascular Diseases Research program (CFDA 93.837) to develop intravenous oxygen (IVO2) therapy as a novel treatment for cardiac arrest. The project focuses on optimizing pH-responsive polymeric microbubbles (PMBs)—gas-carrier particles that safely deliver oxygen directly into the...
- Federal Project Grant Award Summary Award Overview Vanderbilt University Medical Center received a $874,997 Project Grant from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) awarded on September 15, 2025, with completion targeted for August 31, 2026. The grant supports a prospective clinical trial evaluating personalized oxygen therapy targets for critically ill mechanically ventilated adults. Scope of Work The funded...
- Federal Project Grant Award Summary Airalux Medical, Inc. received a $306,872 Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837), effective September 5, 2025, with a completion date of September 4, 2026. The award supports the development and commercialization of a digital incentive spirometry device designed to improve patient adherence and clinical workflows in post-surgical respiratory care. The...
- Pranions, Inc. received a $2.43M Phase II Project Grant from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837), awarded on August 1, 2025, with completion targeted for July 31, 2027. The project funds the development of a next-generation, high-flow portable oxygen concentrator (POC) designed to serve the 1.5 million Americans requiring long-term oxygen therapy (LTOT) for chronic lung diseases including chronic obstructive...
AEROSOL VENTILATION TO REDUCE VENTILATOR INDUCED LUNG INJURY - PROJECT SUMMARY MECHANICAL VENTILATION (MV) IS USED IN AN ICU SETTING WHEN RESPIRATORY FAILURE OCCURS FOR A VARIETY OF REASONS, INCLUDING ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS). THE MORTALITY OF SEVERE ARDS APPROACHES 50% AND EVEN THOSE THAT SURVIVE TYPICALLY REQUIRE MV AND SUFFER LONG-TERM ADVERSE IMPACTS ON THEIR LUNG FUNCTION. THE AGGRESSIVE VENTILATOR SETTINGS USED DURING MC APPLY STRONG MECHANICAL FORCES DURING VENTILATION THAT CAN LEAD TO VENTILATOR-INDUCED LUNG INJURY (VILI) VIA PHYSICAL DISRUPTION OF THE TISSUES AND CELLS AND ACTIVATION OF CYTOTOXIC AND INFLAMMATORY RESPONSES. ALTERNATIVES TO MV, SUCH AS ECMO (EXTRACORPOREAL MEMBRANE OXYGENATION), CAN EFFICIENTLY PERFORM VENTILATION AND OXYGENATION, IS EXORBITANTLY EXPENSIVE, REQUIRES HIGHLY SPECIALIZED TEAMS AND EQUIPMENT THAT IS NOT WIDELY AVAILABLE, AND CARRIES HIGH RISKS OF STROKE, BLEEDING, AND THROMBOSIS. WE PROPOSE THAT AEROSOLIZING LIQUID PERFLUOROCARBONS (LPS) WITH THE INSPIRED AIR DURING MV WILL ACHIEVE MORE RAPID COOLING AND EFFICIENT GAS EXCHANGE, NEGATING THE NEED FOR HIGH VENTILATOR SETTINGS AND THUS REDUCING VILI. TO ACHIEVE THIS, BOUNDLESS SCIENCE IS DEVELOPING A BI-LIQUID AEROSOLIZED THERAPY (BAT) COUPLED TO A MECHANICAL VENTILATOR TO YIELD A BAT SYSTEM (BATS) TO INTRODUCE A FINE PERFLUOROCARBON MIST THAT SIMULTANEOUSLY COOLS THE LUNGS TO REDUCE INFLAMMATION WHILE ENHANCING OXYGEN DELIVERY TO OVERCOME PULMONARY DYSFUNCTION. OUR PRELIMINARY RESULTS INDICATE THAT BATS SUCCESSFULLY AND RAPIDLY COOLED ISOLATED PIG LUNGS TO 32C. WE HYPOTHESIZE THAT BATS WILL ACHIEVE LOW POLYDISPERSITY OF MEDIAN AEROSOL DROPLET TO OBTAIN UNIFORM PULMONARY DISTRIBUTION AND CONSISTENT EFFICACY WHILE USING AN LP MIXTURE THAT ENHANCES CO2 EXHALATION AND THUS IMPROVE PATIENT OUTCOMES. AT THE SAME TIME, THE EVAPORATIVE COOLING IN THE EPITHELIUM WILL FURTHER REDUCE INFLAMMATION BEYOND THE INHERENT ANTI-INFLAMMATORY PROPERTIES OF THE LPS, WHILE LP RECYCLING WITHIN A STANDARD VENTILATOR WILL REDUCING COSTS AND MAKING IT COMMERCIALLY VIABLE FOR THE FIRST TIME. THE OBJECTIVE OF THIS PROPOSAL IS TO PROVIDE PROOF OF CONCEPT THAT BAT COUPLED WITH MV WILL INCREASE PULMONARY OXYGENATION (PAO2/FIO2) BY 50% WITHOUT CAUSING TRAUMA. WE WILL PROGRESS TOWARD THIS OBJECTIVE USING THE FOLLOWING SPECIFIC AIMS. AIM 1) DETERMINE THE OPTIMAL MIXTURE OF LPS THAT HAS LOW LEVEL CYTOTOXICITY AND PROVIDES THE HIGHEST ANTI-INFLAMMATORY EFFECTS IN VITRO. AIM 2) CREATE THE OPTIMAL DROPLET SIZE AND LP RATIO TO EFFECTIVELY INFILTRATE AND COOL ALVEOLI WITH AEROSOLIZED LP. AIM 3) EVALUATE THE OPTIMIZED AEROSOLIZED LP MIXTURE AND DROPLET SIZE FROM AIMS 1 AND 2 IN AN IN VIVO PORCINE MODEL OF ARDS. SUCCESSFUL RESULTS WILL NOT ONLY SHOW THE POTENTIAL OF BATS BUT WILL IMPORTANTLY PROVIDE THE NECESSARY DESIGN GUIDELINES TO DRIVE THE DEVELOPMENT OF A CLINICALLY AND COMMERCIALLY VIABLE SYSTEM.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $0 | 7/8/24 | ||
| Not listed | $0 | 2/3/23 | ||
| Not listed | $0 | 2/3/23 | ||
| Not listed | $300.0k | 9/22/22 | ||
| Not listed | $300.0k | 9/22/22 |